Financials Island Pharmaceuticals Limited
Equities
ILA
AU0000138869
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.068 AUD | +4.62% | +4.62% | -28.42% |
08/05 | Island Pharmaceuticals Reallocates Grant Funding to Dengue Fever Trial; Shares Rally 13% | MT |
16/04 | Island Pharmaceuticals Reports Positive Data from Dose Study of Dengue Medication | MT |
Valuation
Fiscal Period: Giugno | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Capitalization 1 | 7.721 | 7.738 | - | - |
Enterprise Value (EV) 1 | 7.721 | 7.138 | 4.638 | 2.138 |
P/E ratio | -2.94 x | -2.27 x | -4.25 x | -5.23 x |
Yield | - | - | - | - |
Capitalization / Revenue | - | - | - | - |
EV / Revenue | - | - | - | - |
EV / EBITDA | - | -2.46 x | -1.78 x | -0.82 x |
EV / FCF | - | - | - | - |
FCF Yield | - | - | - | - |
Price to Book | - | - | - | - |
Nbr of stocks (in thousands) | 81,268 | 1,13,797 | - | - |
Reference price 2 | 0.0950 | 0.0680 | 0.0680 | 0.0680 |
Announcement Date | 30/08/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: Giugno | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net sales | - | - | - | - |
EBITDA 1 | - | -2.9 | -2.6 | -2.6 |
EBIT 1 | - | -2.9 | -2.6 | -2.6 |
Operating Margin | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -2.9 | -2.6 | -2.5 |
Net income 1 | -2.83 | -2.9 | -2.6 | -2.5 |
Net margin | - | - | - | - |
EPS 2 | -0.0323 | -0.0300 | -0.0160 | -0.0130 |
Free Cash Flow | - | - | - | - |
FCF margin | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - |
Dividend per Share | - | - | - | - |
Announcement Date | 30/08/23 | - | - | - |
Balance Sheet Analysis
Fiscal Period: June | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net Debt 1 | - | - | - | - |
Net Cash position 1 | - | 0.6 | 3.1 | 5.6 |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - |
Assets 1 | - | - | - | - |
Book Value Per Share | - | - | - | - |
Cash Flow per Share | - | - | - | - |
Capex | - | - | - | - |
Capex / Sales | - | - | - | - |
Announcement Date | 30/08/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-28.42% | 51.31L | |
+12.30% | 12TCr | |
+12.15% | 11TCr | |
-8.14% | 2.34TCr | |
-1.69% | 2.18TCr | |
-10.60% | 1.81TCr | |
-41.25% | 1.67TCr | |
-15.33% | 1.6TCr | |
+5.80% | 1.4TCr | |
+28.03% | 1.17TCr |
- Stock Market
- Equities
- ILA Stock
- Financials Island Pharmaceuticals Limited